This inventor holds 1 USPTO granted patent. Top assignees: Assistance Publique - Hopitaux De Paris (Aphp), Fondation Imagine, National Institute of Health and Medical Research. Active years: 2024.
Company Filing History:
1 out of 77 
1 out of 15 
1 out of 1,853 
Years Active: 2024
Title: Innovations in Treating Friedreich Ataxia by Inventor Floriane Petit
Introduction
Floriane Petit, an innovative inventor based in Paris, France, has made significant strides in the field of medical research. With a focus on Friedreich ataxia (FRDA), a genetic disorder that affects the nervous system and muscle coordination, she has developed a pioneering method to treat and predict therapeutic responses in affected patients.
Latest Patents
Floriane Petit holds a patent for her work titled "Treatment and prediction of therapeutic responses in patients suffering from Friedreich ataxia." This groundbreaking patent addresses the underlying mechanisms of FRDA caused by a GAA repeat expansion in the FXN gene. Her research uncovered that FRDA fibroblasts are unable to limit iron uptake, leading to excessive iron accumulation in cells, particularly within the brain and heart. The invention proposes that candidate molecules such as artesunate, dichloroacetate, and Coenzyme-A can enhance transferrin receptor palmitoylation, offering new therapeutic avenues for patients suffering from this debilitating condition.
Career Highlights
Floriane Petit has contributed extensively to her field through her association with notable institutions. She has collaborated with the Institut National de la Santé et de la Recherche Médicale (INSERM) and Fondation Imagine, advancing research efforts aimed at better understanding and treating complex genetic disorders. Her work not only reflects her commitment to innovation but also highlights her influence in medical research.
Collaborations
Throughout her career, Floriane Petit has worked alongside esteemed colleagues, including Anne Agnès Rotig and Arnold Munnich. These collaborations have enriched her research and enabled the development of cutting-edge methodologies in the study of Friedreich ataxia and related health issues.
Conclusion
Floriane Petit's contributions to the understanding and treatment of Friedreich ataxia represent a significant advancement in the field of medical science. Her innovative approach and dedication to research underscore the importance of continued exploration in therapeutic strategies for genetic disorders. Through her patent and collaborative efforts, she is paving the way for better health outcomes for patients with FRDA.